|
| | | | |
|
 | | PREEMPTIVE MEDS, INC. LEADS THE WAY IN THE PRE-DISEASE THERAPEUTIC SPACE, PROVIDING EFFECTIVE ALTERNATIVES TO PHYSICIANS AND THEIR PATIENTS | | | PreEmptive Meds, Inc. | | 10/09/2007 | | | Focusing on the "pre-disease" space of chronic and progressive diseases, and after the recent successful launch of two brands for pre-diabetes and pre-cardiovascular disease in test markets, PreEmptive Meds, Inc. (PMI) announces plans for national expansion.
Led by seasoned pharmaceutical executives, PMI is the first and fastest- growing pre-disease therapeutics company in the world. For the first time, PMI introduces evidence-based, all-natural, proprietary combination therapies exclusively to physicians, just like new prescription drugs are introduced, with fully trained sales professionals, credible peer-reviewed data on efficacy and safety and product training. PMI's new approach is to give physicians and patients effective and safe therapeutic options for managing a variety of pre-disease states before they become irreversible in the hopes of dramatically changing the course of their disease.
Currently, with no known prescription products indicated for pre-disease usage, PMI has the opportunity to define its pre-disease space with its twice- daily formulations. While this market has always existed, there are now defined biomarkers for common chronic diseases, which are clear indicators for the impending full-blown disease. The marketplace of patients "at-risk" for developing a disease is typically five to six times larger than the market for patients who already have disease.
Launched products include PreLipid(TM) and PreLipid Plus(TM) that effectively lower cholesterol and protect cardiovascular health, and PreCrea(TM), which lowers blood sugar levels and restores balance in the pancreas. PMI also recently introduced PreMenora(TM) and PreMenora Plus(TM) for perimenopausal symptoms and bone health. Other pipeline products will include clinically proven plant-based, proprietary formulations to treat symptoms of arthritis, benign prostate enlargement, hemorrhoids, insomnia, early memory loss and a formulation to boost immunity against infections.
"We at PreEmptive Meds are delighted to have the opportunity to offer effective and safe, all natural, proprietary products to physicians for their patients, targeted exclusively for pre-disease," stated Chuck Blitzer, PreEmptive Med's Chief Executive Officer. We believe pre-disease is a significant area of medicine where prescription drugs play little if any role and where PreEmptive Med's proprietary products can make an important therapeutic contribution. "
PMI only promotes its products to physicians as the Company believes that only physicians should make decisions about patients' health and therapeutic options as only physicians are knowledgeable to review the clinical information on the products and recommend them appropriately. The scientific bases of PMI's plant-based products are rooted in the traditional systems of medicine used for centuries in Asia, South America, Europe and the US. Today there is credible evidence from controlled studies of efficacy and safety on plant based ingredients being reported by researchers from around the world. In their proprietary combination-therapy formulations, the Company has for the first time successfully integrated ingredients based on evidence from various traditional systems.
"Most chronic diseases begin and progress because multiple patho- physiologies occur in the body" says Dr. Michael Davidson, Executive Medical Director of Radiant Research in Chicago, IL, a well known researcher and a world expert on lipids and preventive cardiology. "So in order to preempt progression of disease, one must have effective combination therapies that target the various concurrent abnormalities and physicians need to have options to effectively treat disease in their patients as generally no single agent is sufficient." Dr. Davidson, concludes, "PMI's combinations of plant- based ingredients are designed to target elevated cholesterol levels, one of the root causes of heart disease and could be very beneficial when used early in pre-disease. PreLipid Plus, which contains recommended doses of phytosterols, may be useful for statin-intolerant patients who have very few options to treat their cholesterol levels effectively."
According to data from the Centers for Disease Control (CDC) 62% of Americans are taking dietary supplements and many seniors spend approximately $150-200 per month on them. And as baby boomers seek to live healthier and more active lives well into their 70s and 80s, for PMI, this is good news as the Company will find this segment of the population to be large and attractive for it's portfolio of all-natural pre-disease products.
"PMI believes that physicians are becoming increasingly amenable to recommending alternative therapies," says Dr. Joe Fenn, Vice President of Medical Marketing for PMI. "Our launched products have been successfully used by physicians for pre-diabetes and pre-cardiovascular disease management and many physicians are using our products even in disease states along with common prescription medicines as viable options before having to resort to increasing prescription dosages. We have also seen remarkable retention on our therapies, perhaps because our products are 100% natural and also because of our innovative compliance program."
With standardized manufacturing techniques that allow for batch-to-batch consistency and stringent, independently-verified quality control for purity and heavy metal content, PMI is able to bring a traditional pharmaceutical manufacturing and brand management approach to the nutraceutical market.
Blitzer concludes, "Bayer(R) Aspirin, and Tylenol(R) are still leaders in their fields despite the pricing differences with competition because they are continually promoted to the physician and the first established. It is our hope that over time, PMI's formulations and trademarks will become the "Bayer" within the pre-disease therapeutic space."
About PreEmptive Meds, Inc.
Founded in 2006 by seasoned pharmaceutical executives, PreEmptive Meds, Inc., is a pre-disease therapeutic company that offers proprietary, branded, clinically proven, plant-based formulations to physicians. The Company has offices in Minneapolis and Las Vegas. www.preemptivemeds.com.
Financing History: The Company raised $2.5mm between November 2006 and February 2007 from a group of individual ("angel") investors with the help its investment banker, Einhorn Associates of Milwaukee. The capital raised allowed the Company to launch its first two products, in a test in Chicago and the New York City. The Company is currently raising a second angel round of capital as a prelude to a larger institutional round in the 4th quarter, for the express purpose of expanding its sales operations to over 40 territories over the next 8-12 months.
Media Contact: Andrea Martone, andrea@intuitivevision.com, 516. 944.9764, mobile: 917.929.0527
SOURCE PreEmptive Meds, Inc. | |
|
| | | View similar articles: | | |
| | | |
|
 | People who viewed this article were also interested in |  | |  |
|